| Assessment Status | Rapid Review Complete |
| HTA ID | 23077 |
| Drug | Finerenone |
| Brand | Kerendia® |
| Indication | Finerenone (Kerendia®) is indicated for the treatment of chronic kidney disease (with albuminuria) associated with type 2 diabetes (T2D) in adults. |
| Assessment Process | |
| Rapid review commissioned | 20/12/2023 |
| Rapid review completed | 23/01/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that finerenone not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
